Patient Identification

Breyanzi®: CAR T with the broadest eligibility for 2L LBCL patients1
Patient eligibility in TRANSFORM trial vs PILOT trial Patient eligibility in TRANSFORM trial vs PILOT trial

In the 3L+ TRANSCEND trial, patients were refractory or relapsed after ≥2 prior therapies, ≥18 years old, ECOG PS ≤2, LVEF ≥40%, CrCl ≥30 mL/min, and ALT ≤5 × ULN.1

Identify eligible patients early and connect them
with a CAR T cell therapy treatment center

*Median age was 59 years (range: 20-75 years).1
Eligible patients for the PILOT trial were required to be ≥18 years. Median age was 74 years (range: 53-84 years).1,3
PILOT criteria included ALT/AST.1

2L, second-line; 3L, third-line; ALT, alanine transaminase; AST, aspartate aminotransferase; CAR, chimeric antigen receptor; CrCl, creatinine clearance; DLCO, diffusing capacity for carbon monoxide; ECOG PS, Eastern Cooperative Oncology Group performance status; LBCL, large B-cell lymphoma; LVEF, left ventricular ejection fraction; R/R, relapsed or refractory; ULN, upper limit of normal.


Choose Breyanzi, a smart option for a broad range of patients with 2L LBCL1
Select a patient profile
transplant-eligible
transplant-ineligible
CAR T cell therapy 2L patient

Charlotte, 60 years old

2L transplant-eligible R/R ≤12 months

Active, fit, and chemo-sensitive4

Charlotte is a married interior designer who is heavily involved in her local community. She wants to avoid high-dose chemotherapy and transplant.

Clipboard icon

Response to prior therapy

  • CR to DA-EPOCH-R; relapsed at 11 months
Doctor's folder icon

Additional risk factors

  • Double-hit lymphoma
  • No relevant comorbidities
Fitness of body parts icon

Clinical fitness

  • ECOG PS 0
  • LVEF 55%
  • CrCl 70 mL/min
  • Normal bone marrow reserve
  • ANC: 4 × 103 cells/μL
  • Platelets: 400 × 103/μL

All patients depicted are hypothetical.

2L, second-line; ANC, absolute neutrophil count; CR, complete response; CrCl, creatinine clearance; DA-EPOCH-R, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; ECOG PS, Eastern Cooperative Oncology Group performance status; LBCL, large B-cell lymphoma; LVEF, left ventricular ejection fraction; R/R, relapsed or refractory.

CAR T cell therapy 2L patient

Laurie, 68 years old

2L transplant-eligible R/R ≤12 months

Fit, with additional risk factors4

Laurie is a former social worker who is enjoying retirement. She is eager to receive treatment that is right for her.

Fitness of body parts icon

Clinical fitness

  • ECOG PS 1
  • LVEF 55%
  • CrCl 60 mL/min
  • Normal bone marrow reserve prior to R-CHOP

All patients depicted are hypothetical.

2L, second-line; CrCl, creatinine clearance; ECOG PS, Eastern Cooperative Oncology Group performance status; LBCL, large B-cell lymphoma; LVEF, left ventricular ejection fraction; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine; R/R, relapsed or refractory.

CAR T cell therapy 2L patient

Luke, 52 years old

2L transplant-ineligible regardless of time to relapse

Active

Luke is a published author and motivational speaker. He likes taking his dog out for walks, lives an active life, and does not want to plan around chemotherapy appointments.

Clipboard icon

Response to prior therapy

  • Refractory disease to 4 cycles of R-CHOP
Doctor's folder icon

Additional risk factors

  • 1 extranodal site
  • Poor bone marrow reserve
Fitness of body parts icon

Clinical fitness

  • ECOG PS 1
  • LVEF 45%
  • CrCl 55 mL/min

All patients depicted are hypothetical.

2L, second-line; CrCl, creatinine clearance; ECOG PS, Eastern Cooperative Oncology Group performance status; LBCL, large B-cell lymphoma; LVEF, left ventricular ejection fraction; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine.

CAR T cell therapy 2L patient

Betty, 72 years old

2L transplant-ineligible regardless of time to relapse

Betty is a widowed retired school teacher who recently moved in with her daughter’s family. She is interested in receiving treatment that will give her a chance for remission.

Clipboard icon

Response to prior therapy

  • Relapsed at 18 months
Doctor's folder icon

Additional risk factors

  • Diabetes/impaired renal function
Fitness of body parts icon

Clinical fitness

  • ECOG PS 1
  • LVEF 45%
  • CrCl 45 mL/min
  • Normal bone marrow reserve

All patients depicted are hypothetical.

2L, second-line; CrCl, creatinine clearance; ECOG PS, Eastern Cooperative Oncology Group performance status; LBCL, large B-cell lymphoma; LVEF, left ventricular ejection fraction.

Breyanzi for patients with 3L+ LBCL
CAR T cell therapy 3L patient

Robin, 56 years old

Original diagnosis: de novo DLBCL

Robin is a florist in a small city who lives with her spouse. Her 3 adult children live nearby. Robin is knowledgeable about her disease and treatment and is motivated to undergo treatment.

Clipboard icon

Response to prior therapy

First-line therapy

  • Underwent chemoimmunotherapy; achieved CR
  • Relapsed at 18 months

Second-line therapy

  • Underwent high-dose chemotherapy and ASCT
  • Relapsed after 6 months
Doctor's folder icon

Additional risk factors

  • One extranodal site
  • Renal impairment
Fitness of body parts icon

Clinical fitness at second line

  • ECOG PS 1
  • LVEF 56%
  • CrCl 52 mL/min

All patients depicted are hypothetical.

3L, third-line; ASCT, autologous stem cell transplantation; CR, complete response; CrCl, creatinine clearance; DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; LBCL, large B-cell lymphoma; LVEF, left ventricular ejection fraction.

This website is best viewed
using the horizontal display on
your tablet device.

This website is best viewed
using the vertical display on
your mobile device.